Form 4: Cibus CEO Rory Riggs Acquires Warrants in Registered Direct Offering

Cibus, Inc.'s CEO, Rory Riggs, acquired warrants to purchase 8,000,000 shares of Class A Common Stock through a Securities Purchase Agreement related to a registered direct offering.

Summary

• On January 21, 2025, Cibus, Inc. entered into a Securities Purchase Agreement with CEO Rory Riggs.
• Riggs acquired 4,000,000 pre-funded warrants and an accompanying common warrant to purchase up to 4,000,000 shares of Class A Common Stock.
• The combined offering price was $2.4999.
• The transaction is connected to the company's registered direct offering, expected to be completed around January 24, 2025.
• The Issuer's board of directors approved the transaction.
• Pre-funded warrants are exercisable immediately at $0.0001 per share, while common warrants have an exercise price of $2.4999 per share.
• Exercise of both warrants is limited to ensure Riggs doesn't exceed 19.99% ownership of Class A Common Stock or combined voting power.
• Common Warrants will not be exercisable until the Company receives certain approvals from its stockholders required by the applicable rules of the Nasdaq Capital Market.
• The Common Warrants will expire five years following the date of receipt of the Warrant Stockholder Approvals.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The CEO's participation in the capital raise suggests confidence in the company. However, the potential dilution from warrant exercises and the need for stockholder approval for the common warrants temper the overall positive outlook.

Positives

• The CEO's investment could signal confidence in the company's future prospects.
• The capital injection from the warrant exercise could provide additional funding for Cibus' operations.

Risks

• The exercise of warrants could dilute existing shareholders' equity.
• The common warrants are contingent on stockholder approvals, which may not be obtained.
• The CEO's ownership is capped at 19.99%, potentially limiting his long-term influence.

Future Outlook

The registered direct offering is expected to be fully consummated on or about January 24, 2025. The common warrants will not be exercisable until the Company receives certain approvals from its stockholders required by the applicable rules of the Nasdaq Capital Market. The Common Warrants will expire five years following the date of receipt of the Warrant Stockholder Approvals.

Industry Context

Registered direct offerings are a common method for companies to raise capital, often used by smaller or growth-stage companies. Insider participation, such as the CEO purchasing warrants, can be viewed positively by the market as it signals management's confidence in the company's prospects.

Comparison to Industry Standards

• Comparing Cibus's offering to similar biotech companies, the warrant structure and insider participation are relatively standard.
• Companies like Arcadia Biosciences and Calyxt have also utilized registered direct offerings with warrant components.
• The exercise price and ownership limitations are typical provisions to comply with Nasdaq regulations and prevent hostile takeovers.

Related Party Transactions

• The purchase of warrants by CEO Rory Riggs is a related party transaction.

Stakeholder Impact

• Shareholders may experience dilution upon exercise of the warrants.
• The company benefits from the capital raised through the offering.
• Employees may benefit from the company's improved financial position.

Next Steps

• Consummation of the registered direct offering around January 24, 2025.
• Obtaining Warrant Stockholder Approvals for the common warrants to become exercisable.

Key Dates